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A 65-year-old female with a history of mixed connective tissue disease and pulmonary fibrosis on azathioprine, hydroxychloro-
quine, and prednisone (osteoporosis on teriparatide) presented with a 1-month history of hypercalcemia. After discontinuation
of teriparatide, the patient’s hypercalcemia persisted. Further evaluation revealed primary hepatic lymphoma as the source of her
hypercalcemia.
1. Background
Hypercalcemia is a common complication of malignancy as
described by Rodr´ıguez-Gutie´rrez et al. [1]. Typically, this is
mediated by osteolytic metastases or secretion of parathy-
roid hormone related peptide (PTHrP). In both instances,
calcitriol is typically suppressed in order to decrease intesti-
nal absorption, renal reabsorption, and bone resorption of
calcium. In some instances, hypercalcemia can be mediated
by calcitriol. This occurs most commonly in the setting
of sarcoidosis; however, it is reported to also occur in
mycobacterium infections and hematologicmalignancies [2].
Calcitriol-mediated hypercalcemia accounts for less than 1%
of allmalignancy-related hypercalcemia cases and it is usually
found in non-Hodgkin’s lymphoma (NHL), specifically dif-
fuse large B-cell lymphoma (DLBCL), aswas the casewith our
patient. Furthermore, this may be the first reported case of
PHL potentially related to immunosuppressive therapy with
hydroxychloroquine, azathioprine, and prednisone formixed
connective tissue disorder and pulmonary fibrosis.
2. Case Presentation
A 65-year-old female with a history of mixed connec-
tive tissue disease and pulmonary fibrosis on azathioprine,
hydroxychloroquine, and prednisone (osteoporosis previ-
ously on teriparatide) presented with a 1-month history of
hypercalcemia.The patient initially presented to her rheuma-
tologist with complaints of weakness, dizziness, confusion,
and difficulty with ambulation. Laboratory workup during
that visit revealed hypercalcemia at 12.0mg/dL (normal: 8.7–
10.7mg/dL) and albumin of 3.2 g/dL (normal: 3.5–4.8 g/dL).
Her hypercalcemia was attributed her teriparatide use and
this medication was discontinued; however, when her symp-
toms persisted, she presented to her primary care physician
who found a calcium level of 13.6mg/dL. She was admitted
to the hospital where a skeletal survey was negative for lytic
lesions and serum electrophoresis (SPEP) showed no mono-
clonal band. Further testing determined that she had PTH-
independent hypercalcemia; parathyroid hormone (PTH)
was decreased at 6 pg/mL (normal: 10–65 pg/mL), PTHrP
was normal at 14 pg/mL (normal: 14–27 pg/mL), calcifediol
(25-hydroxyvitamin D) was decreased at 18 ng/mL (defi-
ciency < 20 ng/dL; insufficiency: 20–29 ng/mL; optimal ≥
30 ng/dL), and calcitriol (1,25-dihydroxyvitamin D) was ele-
vated at 159 pg/mL (normal: 18–72 pg/mL). Repeat calcitriol
and PTH were 197 pg/mL and 6 pg/mL, respectively. The
patient was rehydrated with intravenous (IV) fluids, and she
received calcitonin, leading to improvement of her calcium to
10.7mg/dL at the time of discharge. After discharge, she
developed symptoms of fatigue, polydipsia, and polyuria.
She presented to her primary care physician who found a
calcium level of 15.6mg/dL and was again admitted to the
hospital. Upon further questioning, the patient did report
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Figure 1: Axial view of primary hepatic lymphoma.
a twenty-three-pound weight loss during the preceding two-
month span but denied any fevers, chills, or drenching night
sweats.
3. Investigation
Complete blood count revealed hemoglobin of 7.5 g/dL (nor-
mal: 12–16 g/dL), hematocrit of 22.4% (normal: 37–47%),
and mean corpuscular volume of 104.9 fL (83–101 fL). Blood
urea nitrogen was 21mg/dL (normal: 7-23mg/dL) and crea-
tinine was 0.99mg/dL (normal: 0.5–1.2mg/dL). Serum iron,
ferritin, transferrin, total iron binding capacity, transferrin
saturation, folate, and vitamin B12 levels were all within
normal limits. A peripheral blood smear was negative for any
schistocytosis. Aspartate aminotransferase (AST), alanine
aminotransferase (ALT), total bilirubin, and direct bilirubin
were all within normal limits. Alpha-fetoprotein (AFP) and
carcinoembryonic antigen (CEA) were within normal limits
at 1.4 ng/mL (normal< 6.1 ng/mL) and 0.8 ng/mL (normal: 0–
3 ng/mL in nonsmokers), respectively. Alkaline phosphatase
(ALP) and lactic dehydrogenase (LDH) were elevated at
121 IU/L (normal: 30–115 IU/L) and 687 IU/L (normal: 110–
240 IU/L), respectively. Hepatitis panel was negative for any
evidence of a current infection or previous exposure.
Computed tomography (CT) of the chest did not reveal
any lymphadenopathy or findings suggestive of granuloma-
tous disease. CT of the abdomen and pelvis revealed an 11.3
× 10.7 × 11.1 cm mass in the right lobe of the liver with
central areas of hypoenhancement likely reflecting necrosis
(Figures 1 and 2). Another hypodense lesion, inferior to
the previous mass, measuring 6 × 7mm was also noted.
Several mildly prominent pericaval, aortocaval, and pericaval
lymph nodes were seen as well. Of note, no bony lesions
were appreciated on either scan. A four-phase CT scan of
the liver revealed no arterial enhancement of the mass,
but the solid components demonstrated progressive delayed
enhancement. Furthermore, there was mass effect on the
right anterior portal vein and right hepatic vein without any
vascular invasion. The smaller hypodense lesion inferior to
the larger mass did not demonstrate enhancement which was
compatible with findings of a cyst. Of note, CT of the head did
not reveal any bony lesions or evidence of metastatic disease
which was confirmed bymagnetic resonance imaging (MRI).
Figure 2: Coronal view of primary hepatic lymphoma.
Given the history concerning for malignancy coupled
with the CT findings, the patient underwent a liver biopsy
for tissue diagnosis of the lesion. Fine needle aspirate
of the liver mass revealed malignant cells while cytology
revealed CD45+, CD20+, CD10−, CD30−, BCL2−, BCL6+,
and SOX10−. These findings were most consistent with a
germinal cell center DLBCL.
4. Differential Diagnosis
The differential diagnosis of her PTH-independent hyper-
calcemia included teriparatide administration, milk-alkali
syndrome, paraneoplastic syndrome, granulomatous disease,
metastatic disease, and hematological malignancy, particu-
larly lymphoma. On the lymphoma spectrum, those with
non-Hodgkin’s lymphoma [3–5], chronic myeloid leukemia
(blast phase) [6], and adult T-cell leukemia-lymphoma
may have PTHrP-induced hypercalcemia [7, 8]. Teriparatide
administration was unlikely because the effects of hypercal-
cemia are transient, usually resolving sixteen hours after the
last administration [9]. Milk-alkali syndrome was unlikely
given that she reported the consumption of only six tablets
over a span of a month. CT imaging was negative for any
signs of granulomatous disease. Lastly, a bone scan, a skeletal
survey, and CT imaging were negative for any lytic bone
lesions which made metastatic disease as the cause of her
hypercalcemia less likely.
Common differential diagnoses for a solitary hepatic
lesion included hepatic cyst, hemangioma, focal nodular
hyperplasia, hepatic adenoma, regenerative nodules, hep-
atocellular carcinoma, cholangiocarcinoma, or metastatic
disease. Very rarely, a solitary hepatic lesion can be due
to soft tissue sarcomas, hepatoblastoma, or non-Hodgkin’s
lymphoma (NHL).
5. Treatment
The patient was initially given prednisone 40mg daily due
to concerns of hypercalcemia secondary to granulomatous
disease. This had been tapered down to prednisone 20mg
daily prior to the liver biopsy results. In addition, the patient
was given IV fluids and given a single dose of zoledronic
acid which led to an improvement of her hypercalcemia to
10.6mg/dL. Upon diagnosis of her DLBCL, the patient was
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Table 1: PTH-dependent hypercalcemia etiologies and percent
of occurrence. Parathyroid gland hyperplasia includes the multi-
ple endocrine neoplasia (MEN) syndromes, hyperparathyroid jaw
tumor syndrome, and familial isolated hyperparathyroidism. Rarely,
primary parathyroid gland malignancy is the cause [3].
PTH-dependent hypercalcemia
etiology Prevalence
Single benign adenoma 80–85%
Parathyroid gland hyperplasia 10–15%
Parathyroid malignancy Less than 1%
initiated on R-CHOP chemotherapy (rituximab, cyclophos-
phamide, doxorubicin, vincristine, and prednisone). At time
of discharge, the patient’s calcium level was 10.2mg/dL and
remained normalized at 9.8mg/dL in her subsequent follow-
up.
6. Outcome and Follow-Up
Given her age, elevated LDH, Eastern Cooperative Oncology
Group (ECOG) performance status of two, and Ann Arbor
stage IV disease, the patient’s International Prognostic Index
(IPI) was four, corresponding to 26% five-year survival [10].
The patient was initiated on her first cycle of chemotherapy
during her hospitalization. Upon discharge, the patient and
her family sought to transition her care to another tertiary
hospital closer to her home.
7. Discussion
Hypercalcemia is a complex topic with many etiologies.
From the furthest viewpoint, it can be categorized into PTH-
dependent (PTHD) and PTH-independent (PTHI) causes.
PTHD hypercalcemia can be suspected when elevated cal-
cium levels are accompanied by normal to high normal PTH
levels, suggesting inadequate suppression of PTH. The most
common cause of PTHD is primary hyperparathyroidism
(PHPT). A benign, single adenoma accounts for 80–85% of
cases. Parathyroid gland hyperplasia including the multiple
endocrine neoplasia (MEN) syndromes, hyperparathyroid
jaw tumor syndrome, and familial isolated hyperparathy-
roidism is the culprit in 10–15% of cases. Less than 1% of
the time, parathyroid malignancy is the etiology of PTHD
hypercalcemia (Table 1) [3]. In our patient, PTH levels were
adequately suppressed at 6 pg/mL which suggested that she
did not have PTH-dependent hypercalcemia.
PTH-independent hypercalcemia has many etiologies.
This includes solid tumors, hematologic malignancies, milk-
alkali syndrome, medications, vitamin D intoxication, gran-
ulomatous disease, and calcitriol-mediated hypercalcemia.
Hypercalcemia mediated by PTHrP accounts for 80%
of PTHI hypercalcemia cases secondary to malignancy.
Osteolytic metastasis, often seen in multiple myeloma and
breast cancer, is mediated by interleukin and accounts for
20% of malignancy-related hypercalcemia cases. In both of
these scenarios, calcitriol is suppressed in order to decrease
the intestinal absorption, renal reabsorption, and bone
Table 2: The etiologies and frequency of PTH-independent hyper-
calcemia related to malignancy [2, 4].
Hypercalcemia due to malignancy
etiology Prevalence
PTHrP-mediated 80%
Osteolytic lesions 20%
Calcitriol-mediated <1%
Table 3: Calcitriol-mediated causes of hypercalcemia and their
prevalence. Information gathered from a review of 101 proven
calcitriol-mediated hypercalcemia cases [2].
Calcitriol-mediated hypercalcemia
etiology Prevalence
Sarcoidosis 49%
Hematologic malignancy 17%
Infections 8%
Solid organ malignancy 5%
Other granulomatous conditions 4%
Idiopathic disease 3%
Diagnosis not made 14-15%
resorption of calcium. Less than 1% of malignancy-related
hypercalcemia cases aremediated by calcitriol (Table 2) [2, 4].
Elevated calcium and calcitriol levels accompanied with
decreased levels of PTH are highly suggestive of calcitriol-
mediated disease. In the calcitriol-mediated hypercalcemia
umbrella, sarcoidosis accounts for 49% of cases. Hemato-
logic malignancies account for 17% of calcitriol-mediated
hypercalcemia cases. Infection, solid organmalignancy, other
granulomatous conditions, such as tuberculosis and systemic
fungal infections, and idiopathic disease account for 8%,
5%, 4%, and 3% of cases, respectively (Table 3) [2]. Of
the hematologic malignancies, the most common source
of calcitriol-mediated hypercalcemia is non-Hodgkin’s lym-
phoma, specifically DLBCL.
The mechanism of action of calcitriol-mediated hyper-
calcemia related to malignancy is unclear. Normally, 1-alpha
hydroxylase is expressed in the kidneys and will convert
inactive calcifediol to active calcitriol. It has been theorized
that, in lymphomas, surrounding macrophages may have 1-
alpha hydroxylase activity which contributes to the elevation
of calcitriol levels. Hewison et al. demonstrated this phe-
nomenon using immunolocalization [11].
Primary hepatic lymphoma accounts for 0.016% of all
non-Hodgkin’s lymphoma cases and 0.4% of primary extra-
nodal NHL. The majority of primary hepatic lymphomas
are found to be DLBCL [12]. Other pathologies are rare but
have been reported in the literature. These include mucosa-
associated lymphoid tissue (MALT), lymphoblastic, mantle
cell, follicular, and Burkitt lymphomas [5].
Etiologic factors associated with PHL are human immun-
odeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C
virus (HCV), Epstein-Barr Virus (EBV), immunosuppressive
therapy, and autoimmune diseases. Of note, HCV is reported
in 40–60% of cases [6]. As far as immunosuppressive therapy
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is concerned, PHL has been well described in patients
prescribed methotrexate for rheumatoid arthritis [13].
PHL more commonly occurs in the fifth decade of life
and is three times more common in males [13]. Laboratory
tests can help differentiate between hepatocellular carcinoma
and PHL; ALP and LDH are typically elevated while AFP and
CEA are within normal ranges as was the case in our patient
[3, 6]. Radiographic imaging can help define the extent of
disease; however, there are no characteristic findings that can
clearly differentiate PHL from other differentials. Typically,
imaging will show a solitary mass in 60% of PHL cases as
seen in our patient (Figure 1). CT usually shows minimal to
no enhancement on all phases likely due to the poor vascular
supply. It is not uncommon to see a central hypodensity
within the mass, commonly due to tissue necrosis [14].
Overall, there is no pathognomonic radiographic finding in
PHL and therefore biopsy is considered the gold standard for
the diagnosis of PHL. FNA should not be performed as the
tissue may be necrotic and result in a false-negative result
[6, 15].
Standard therapy for DLBCL is chemotherapy [6], partic-
ularly with the regimen of R-CHOP (rituximab, cyclophos-
phamide, doxorubicin, vincristine, and prednisone). Other
treatment regimens with and without radiotherapy and
surgery have also been described in the literature. For small
localizing lesions, surgical resection may be sufficient as a
stand-alone therapy, but this is not routinely practiced as
relapse after surgery is common [5].
There aremultiple observational and retrospective studies
on survival rates for PHL. One study from theMDAnderson
Cancer Center followed up 24 PHL cases for 20 years.
Complete remission was achieved in 85% of cases and event-
free 5-year survival rate was 70% [15].
8. Conclusion
Calcitriol-mediated hypercalcemia in malignancy is rare and
accounts for less than 1% of all malignancy-related hyper-
calcemia cases. When present, it most commonly occurs
in NHL, specifically DLBCL. PHL has known association
with immunosuppressive therapy and autoimmune diseases
and is well described in patients with rheumatoid arthritis
prescribed methotrexate. To our knowledge, this is the
first reported case of PHL potentially related to immuno-
suppressive therapy with hydroxychloroquine, azathioprine,
and prednisone for mixed connective tissue disorder and
pulmonary fibrosis.
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